Pubblicazioni

Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer

2019 - SURGICAL ONCOLOGY

Petrioli, Roberto; Marrelli, Daniele; Roviello, Franco; D'Ignazio, Alessia; Torre, Pamela; Chirra, Martina; Savelli, Vinno; Ambrosio, Maria Raffaella; Francini, Guido; Calomino, Natale; Farsi, Marco; Vernillo, Remo; Francini, Edoardo

Hsa-miR-210-3p expression in breast cancer and its putative association with worse outcome in patients treated with Docetaxel

2019 - SCIENTIFIC REPORTS

Pasculli, B; Barbano, R; Rendina, M; Fontana, A; Copetti, M; Mazza, T; Valori, Vm; Morritti, M; Maiello, E; Graziano, P; Murgo, R; Fazio, Vm; Esteller, M; Parrella, P